Neopharmed Gentili, a pharmaceutical company specialized in the marketing of high therapeutic value solutions controlled by Ardian together with the Del Bono family, has entered into an agreement with Bayer for the acquisition of rights in Italy and Japan of the historical brands Minias and Noctamid (Italy) and Evamyl (Japan), which are products used in the short-term treatment of insomnia, in particular anxiety-induced insomnia.
Giovannelli e Associati assisted Neopharmed Gentili in all legal aspects of the transaction with a team led by partner Fabrizio Scaparro and comprising senior associate Laura Bernardi, associate Paola Pagani and trainee Camilla Lanzafame for corporate and commercial matters, partner Riccardo Pontremoli trainee Carlo Pilia for the administrative/regulatory matters and partner Alessandra Feller with associate Ginevra Lombardi for the IP matters.
Neopharmed Gentili was assisted by Loeschner Rechtsanwaltsgesellschaft mbH for the German law aspects of the transaction with the partner Ramin Loeschner and Vasco da Gama law firm for the Japanese law aspects of the transaction with a team led by the partner Peter Tam assisted by the associate Yuko Kaneko.
Read More: